财中社11月21日电四环医药（00460）发布公告称，其旗下非全资附属公司惠升生物与另一非全资附属公司渼颜空间达成独家授权合作，涉及惠升生物研发的用于减重的司美格鲁肽注射液。该注射液作为一种长效GLP-1受体激动剂，已在中国大陆地区获得减重适应症的临床批准，并且在2型糖尿病适应症方面已完成III期临床入组。
根据合作协议，惠升生物将作为司美格鲁肽减重适应症产品的上市许可持有人，授予渼颜空间在中国大陆地区的独家经销权及相关知识产权使用权。惠升生物将向渼颜空间提供独家生产和供应该合作产品的服务。此次合作预计将加速产品的研发进程，并在市场准入方面带来积极影响，提升双方的企业价值，实现资源共享和优势互补。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.